UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...

The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...

Motif ? one of the clinical trial technology market's fastest growing companies ? continues contributing to major innovations in how clinical trial patient data are collected, with Chief Scientific ...

In a 2024 review, Richardson and colleagues noted that the immunomodulatory drugs thalidomide, lenalidomide (Revlimid), and ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

Beam Therapeutics Inc. has raked in $255 million in cash from the sale of its spinout, Orbital Therapeutics, to Bristol Myers ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

GSK and UK-based rival AstraZeneca have revealed billions of dollars in US investment in recent months in response to ...

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology ...

hubXchange’s Antibody Therapeutics Xchange Boston 2026 brings together senior-level scientists, R&D leaders, and executives ...